C 
31.24
+4.59%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Celldex Therapeutics
From its filings with the US Securities and Exchange Commission
Celldex Therapeutics is based in Hampton, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CLDX. The SEC classifies its business as in vitro & in vivo diagnostic substances. In the fiscal year to 31 December 2025, it reported revenue of $1.5m and a net loss of $258.8m. At that date it held total assets of $583.0m and shareholders' equity of $527.2m.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 May 1986
- Employees
- 198
- Website
- celldextherapeutics.com ↗
- Head office
- 53 FRONTAGE ROAD, HAMPTON, NJ, 08827
- Incorporated in
- DE
- Classification
- In Vitro & In Vivo Diagnostic Substances
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Anthony MarucciPresident, Chief Executive Officer, Director, since 2008$9.2m
- Mr. Sam MartinChief Financial Office, Senior Vice President, Secretary$2.8m
- Dr. Tibor KelerExecutive Vice President, Chief Scientific Officer$3.3m
- Mr. Freddy JimenezSenior Vice President, General Counsel$2.2m
- Ms. Sarah CavanaughSenior Vice President - Corporate Affairs and Administration
- Ms. Elizabeth CrowleySenior Vice President, Chief Product Development Officer$2.9m
- Dr. Margo Heath-ChiozziSenior Vice President - Regulatory Affairs$2.9m
- Ms. Teri LawverSenior Vice President, Chief Commercial Officer
- Dr. Ronald PepinSenior Vice President and Chief Business Officer$1.2m
- Dr. Diane YoungSenior Vice President, Chief Medical Officer$3.0m
- Ms. Denice TorresDirector
- Mr. Keith BrownlieIndependent Director$500,549
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 49
- Environment
- 34
- Social
- 41
- Governance
- 72
- Women in the workforce
- 59%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Innovative Drug Pipeline: Celldex Therapeutics Inc has a diverse and promising pipeline of innovative drug candidates, positioning the company for potential future success.
- Strong Intellectual Property: The company holds a valuable portfolio of intellectual property rights, providing a competitive advantage and protection for their novel therapies.
- Extensive Research and Development Capabilities: Celldex Therapeutics Inc invests significantly in research and development, fostering a culture of innovation and allowing for continuous advancement in their product offerings.
- Established Partnerships: The company has formed strategic partnerships with renowned organizations, further supporting their research efforts and facilitating potential commercialization opportunities.
Weaknesses
- Financial Dependence: Celldex Therapeutics Inc heavily relies on external funding sources, which may pose a risk to the company's financial stability if funding becomes limited or unavailable.
- Limited Product Diversification: The current product portfolio of Celldex Therapeutics Inc mainly focuses on oncology treatments, making the company vulnerable to market fluctuations and risks associated with a single therapeutic area.
- Clinical Trial Risks: The success of Celldex Therapeutics' drug candidates heavily depends on the outcomes of clinical trials. The failure or delay of these trials can significantly impact the company's financial performance.
Opportunities
- Growing Demand for Innovative Therapies: The healthcare industry is witnessing an increasing demand for novel and effective therapies, presenting a significant market opportunity for Celldex Therapeutics Inc to commercialize their products.
- Expansion into New Geographic Markets: The company has the potential to expand its market presence beyond its current geographic scope, tapping into new regions and accessing previously untapped patient populations.
- Strategic Collaborations: Collaborating with other biopharmaceutical companies or research institutions can provide additional opportunities for Celldex Therapeutics Inc to leverage their expertise, accelerate research, and enhance market reach.
Threats
- Intense Competition: The biopharmaceutical industry is highly competitive, with numerous established players and emerging startups. Celldex Therapeutics Inc faces the risk of competitors developing similar or superior therapies that could potentially erode their market share.
- Regulatory Challenges: Stringent regulatory requirements governing drug development and approval processes can introduce delays and uncertainties for Celldex Therapeutics Inc's pipeline candidates, posing potential risks to their commercialization plans.
- Pricing Pressure: The healthcare industry faces ongoing pricing pressure from payers and governmental authorities. Celldex Therapeutics Inc may encounter challenges in pricing their therapies competitively while sustaining profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.